Pliant Therapeutics to lay off 45% of Workforce in Restructuring Move

MT Newswires Live

May 02

Pliant Therapeutics (PLRX) said late Thursday it is laying off around 45% of its workforce in a strategic restructuring targeted at preserving cash reserves while it completes late-stage clinical trials.

Pliant said it expects to complete the restructuring process by the end of Q2, as it focuses on maintaining its late-stage clinical trial execution capabilities.

The company said it expects topline data from its phase 2b/3 trial of bexotegrast in patients with idiopathic pulmonary fibrosis in Q2, and will determine its next steps afterwards.

The company anticipates to recognize about $3.6 million in total for severance and related benefits for employees laid off under the reduction in force, according to a regulatory filing.

Price: 1.65, Change: +0.02, Percent Change: +1.54

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2532256188"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2532256188\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2532256188?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-02 23:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2532256188","market":"us","top_or_hot":-1,"title":"Pliant Therapeutics to lay off 45% of Workforce in Restructuring Move","media":"MT Newswires Live","content":"<html><body><p> Pliant <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (PLRX) said late Thursday it is laying off around 45% of its workforce in a strategic restructuring targeted at preserving cash reserves while it completes late-stage clinical trials.</p><p>Pliant said it expects to complete the restructuring process by the end of Q2, as it focuses on maintaining its late-stage clinical trial execution capabilities.</p><p>The company said it expects topline data from its phase 2b/3 trial of bexotegrast in patients with idiopathic pulmonary fibrosis in Q2, and will determine its next steps afterwards.</p><p>The company anticipates to recognize about $3.6 million in total for severance and related benefits for employees laid off under the reduction in force, according to a regulatory filing.</p><p>Price: 1.65, Change: +0.02, Percent Change: +1.54</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pliant Therapeutics to lay off 45% of Workforce in Restructuring Move</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPliant Therapeutics to lay off 45% of Workforce in Restructuring Move\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-05-02 23:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Pliant <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (PLRX) said late Thursday it is laying off around 45% of its workforce in a strategic restructuring targeted at preserving cash reserves while it completes late-stage clinical trials.</p><p>Pliant said it expects to complete the restructuring process by the end of Q2, as it focuses on maintaining its late-stage clinical trial execution capabilities.</p><p>The company said it expects topline data from its phase 2b/3 trial of bexotegrast in patients with idiopathic pulmonary fibrosis in Q2, and will determine its next steps afterwards.</p><p>The company anticipates to recognize about $3.6 million in total for severance and related benefits for employees laid off under the reduction in force, according to a regulatory filing.</p><p>Price: 1.65, Change: +0.02, Percent Change: +1.54</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PLRX","symbol_name":"Pliant Therapeutics, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2532256188","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2532256188","pubTimestamp":1746198500,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Pliant Therapeutics  said late Thursday it is laying off around 45% of its workforce in a strategic restructuring targeted at preserving cash reserves while it completes late-stage clinical trials.Pliant said it expects to complete the restructuring process by the end of Q2, as it focuses on maintaining its late-stage clinical trial execution capabilities.The company said it expects topline data from its phase 2b/3 trial of bexotegrast in patients with idiopathic pulmonary fibrosis in Q2, and will determine its next steps afterwards.The company anticipates to recognize about $3.6 million in total for severance and related benefits for employees laid off under the reduction in force, according to a regulatory filing.Price: 1.65, Change: +0.02, Percent Change: +1.54","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PLRX":"Pliant Therapeutics, Inc.","BK4139":"生物科技","BK4007":"制药","LENZ":"Therapeutics"},"translate_title":"Pliant Therapeutics将在重组中裁员45%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"PLRX":0.9},"content_text":"Pliant Therapeutics (PLRX) said late Thursday it is laying off around 45% of its workforce in a strategic restructuring targeted at preserving cash reserves while it completes late-stage clinical trials.Pliant said it expects to complete the restructuring process by the end of Q2, as it focuses on maintaining its late-stage clinical trial execution capabilities.The company said it expects topline data from its phase 2b/3 trial of bexotegrast in patients with idiopathic pulmonary fibrosis in Q2, and will determine its next steps afterwards.The company anticipates to recognize about $3.6 million in total for severance and related benefits for employees laid off under the reduction in force, according to a regulatory filing.Price: 1.65, Change: +0.02, Percent Change: +1.54","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}